ArticleDrugs in R&D2026

Preclinical Evaluation of AHT-102, a CLDN18.2 × CD3 Bispecific Antibody: Pharmacokinetics, Anti-Tumor Efficacy, Tissue Distribution, and Safety Profile.

Huilun Chu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.